Supernus Pharmaceuticals Income from Continuous Operations 2011-2024 | SUPN

Supernus Pharmaceuticals income from continuous operations from 2011 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Supernus Pharmaceuticals Annual Income from Continuous Operations
(Millions of US $)
2023 $1
2022 $61
2021 $53
2020 $127
2019 $113
2018 $111
2017 $57
2016 $91
2015 $14
2014 $-11
2013 $-92
2012 $-46
2011 $-23
2010 $-39
Supernus Pharmaceuticals Quarterly Income from Continuous Operations
(Millions of US $)
2024-09-30 $38
2024-06-30 $20
2024-03-31 $0
2023-12-31 $1
2023-09-30 $-16
2023-06-30 $-1
2023-03-31 $17
2022-12-31 $25
2022-09-30 $2
2022-06-30 $8
2022-03-31 $26
2021-12-31 $2
2021-09-30 $22
2021-06-30 $24
2021-03-31 $6
2020-12-31 $31
2020-09-30 $40
2020-06-30 $35
2020-03-31 $22
2019-12-31 $33
2019-09-30 $29
2019-06-30 $33
2019-03-31 $18
2018-12-31 $26
2018-09-30 $28
2018-06-30 $31
2018-03-31 $26
2017-12-31 $14
2017-09-30 $16
2017-06-30 $17
2017-03-31 $10
2016-12-31 $14
2016-09-30 $62
2016-06-30 $10
2016-03-31 $5
2015-12-31 $7
2015-09-30 $4
2015-06-30 $2
2015-03-31 $1
2014-12-31 $4
2014-09-30 $-2
2014-06-30 $3
2014-03-31 $-16
2013-12-31 $-22
2013-09-30 $-24
2013-06-30 $-27
2013-03-31 $-18
2012-12-31 $-14
2012-09-30 $-13
2012-06-30 $-10
2012-03-31 $-9
2011-12-31 $6
2011-09-30 $-10
2011-06-30 $-9
2011-03-31 $-10
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.089B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00